Xiaodong Wang - C Rad Pres China
CRAD-B Stock | SEK 30.60 0.80 2.55% |
Insider
Xiaodong Wang is Pres China of C Rad AB
Age | 44 |
Phone | 46 18 66 69 30 |
Web | https://www.c-rad.se |
Xiaodong Wang Latest Insider Activity
Tracking and analyzing the buying and selling activities of Xiaodong Wang against C Rad stock is an integral part of due diligence when investing in C Rad. Xiaodong Wang insider activity provides valuable insight into whether C Rad is net buyers or sellers over its current business cycle. Note, C Rad insiders must abide by specific rules, including filing SEC forms every time they buy or sell C Rad'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Xiaodong Wang over three months ago Disposition of 6981 shares by Xiaodong Wang of BeiGene at 191.9621 subject to Rule 16b-3 | ||
Xiaodong Wang over six months ago Disposition of 4099 shares by Xiaodong Wang of BeiGene at 260.305 subject to Rule 16b-3 |
C Rad Management Efficiency
The company has return on total asset (ROA) of 0.0422 % which means that it generated a profit of $0.0422 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0317 %, meaning that it generated $0.0317 on every $100 dollars invested by stockholders. C Rad's management efficiency ratios could be used to measure how well C Rad manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Fredrik Lofman | RaySearch Laboratories AB | 45 | |
Maja Nilsson | Biotage AB | N/A | |
Mikael Ekholm | Boule Diagnostics AB | 61 | |
Michael Eliott | Boule Diagnostics AB | N/A | |
Aishat Bislieva | Boule Diagnostics AB | N/A | |
Prof MD | Bonesupport Holding AB | 80 | |
Mattias Isaksson | Boule Diagnostics AB | N/A | |
Johan Lof | RaySearch Laboratories AB | 54 | |
Petra Duprez | Biotage AB | 58 | |
Urban Strindlov | CellaVision AB | 59 | |
Jonas Stahlberg | Biotage AB | 48 | |
Julien Veyssy | CellaVision AB | 40 | |
JonSverre Schanche | Biotage AB | 66 | |
Christina Hugosson | Boule Diagnostics AB | 60 | |
CS BSc | Biotage AB | 50 | |
Fergus MacLeod | Bonesupport Holding AB | 53 | |
Jesper Soderqvist | Boule Diagnostics AB | 57 | |
Olof Nord | Biotage AB | 48 | |
Yve Thorenburg | CellaVision AB | 65 | |
Helena Borjesson | Boule Diagnostics AB | N/A | |
AnnMarie Thor | Bonesupport Holding AB | N/A |
Management Performance
Return On Equity | 0.0317 | |||
Return On Asset | 0.0422 |
C Rad AB Leadership Team
Elected by the shareholders, the C Rad's board of directors comprises two types of representatives: C Rad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CRAD-B. The board's role is to monitor C Rad's management team and ensure that shareholders' interests are well served. C Rad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, C Rad's outside directors are responsible for providing unbiased perspectives on the board's policies.
Xiaodong Wang, Pres China | ||
Tim Thurn, CEO Pres | ||
Ivan Astralaga, Pres Americas | ||
Hakan Axelsson, Chief Officer | ||
Emelie Gozzi, Global Director | ||
Priscilla Kazumba, Digital Coordinator | ||
Lars Levin, Interim Officer |
CRAD-B Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is C Rad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0317 | |||
Return On Asset | 0.0422 | |||
Profit Margin | 0.02 % | |||
Operating Margin | 0.07 % | |||
Current Valuation | 1.23 B | |||
Shares Outstanding | 33.8 M | |||
Shares Owned By Insiders | 52.18 % | |||
Shares Owned By Institutions | 18.00 % | |||
Price To Earning | 46.24 X | |||
Price To Book | 5.61 X |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in CRAD-B Stock
C Rad financial ratios help investors to determine whether CRAD-B Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CRAD-B with respect to the benefits of owning C Rad security.